ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
15 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
15
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
|
|
delivercn
|
126 |
37K |
2 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
126
|
37K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Medgate extends licence agreement and plans to expand use
|
|
delivercn
|
151 |
50K |
43 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
151
|
50K
|
43
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
|
|
delivercn
|
126 |
37K |
8 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
126
|
37K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
|
|
delivercn
|
126 |
37K |
12 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
126
|
37K
|
12
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
|
|
delivercn
|
126 |
37K |
23 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
126
|
37K
|
23
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
|
|
delivercn
|
126 |
37K |
3 |
06/07/22 |
06/07/22 |
ASX - By Stock
|
126
|
37K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Update
|
|
delivercn
|
132 |
46K |
18 |
05/07/22 |
05/07/22 |
ASX - By Stock
|
132
|
46K
|
18
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Cough detection patent granted in Australia and Japan
|
|
delivercn
|
47 |
14K |
10 |
05/07/22 |
05/07/22 |
ASX - By Stock
|
47
|
14K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Update
|
|
delivercn
|
132 |
46K |
8 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
132
|
46K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
4 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Update
|
|
delivercn
|
132 |
46K |
3 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
132
|
46K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
2 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
2
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
7 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
7
|
|
ASX - By Stock
|
RAP |
Re:
Suspend Trade of Rap Shares
|
|
delivercn
|
11 |
5.2K |
14 |
26/06/22 |
26/06/22 |
ASX - By Stock
|
11
|
5.2K
|
14
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
delivercn
|
377 |
142K |
5 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
377
|
142K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
delivercn
|
377 |
142K |
5 |
24/06/22 |
24/06/22 |
ASX - By Stock
|
377
|
142K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp to present at Gold Coast Investment Showcase
|
|
delivercn
|
93 |
31K |
1 |
23/06/22 |
23/06/22 |
ASX - By Stock
|
93
|
31K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
delivercn
|
425 |
125K |
25 |
23/06/22 |
23/06/22 |
ASX - By Stock
|
425
|
125K
|
25
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
delivercn
|
425 |
125K |
17 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
125K
|
17
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
delivercn
|
425 |
125K |
9 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
125K
|
9
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
delivercn
|
425 |
125K |
21 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
125K
|
21
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Investor Webinar
|
|
delivercn
|
118 |
37K |
7 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
118
|
37K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
Vote NO Pfizer offer
|
|
delivercn
|
555 |
189K |
8 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
555
|
189K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
delivercn
|
377 |
142K |
11 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
377
|
142K
|
11
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
delivercn
|
377 |
142K |
23 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
377
|
142K
|
23
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
delivercn
|
92 |
43K |
2 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
92
|
43K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
delivercn
|
88 |
40K |
17 |
06/06/22 |
06/06/22 |
ASX - By Stock
|
88
|
40K
|
17
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Trading Halt
|
|
delivercn
|
98 |
45K |
4 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
98
|
45K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
delivercn
|
466 |
160K |
10 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
466
|
160K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
delivercn
|
466 |
160K |
4 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
466
|
160K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
delivercn
|
466 |
160K |
10 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
466
|
160K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
delivercn
|
466 |
160K |
3 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
466
|
160K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Valuing ResApp Health
|
|
delivercn
|
466 |
160K |
11 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
466
|
160K
|
11
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
24 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
24
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
7 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
7
|
|
ASX - By Stock
|
RAP |
Re:
rap chart
|
|
delivercn
|
4.6K |
2.1M |
19 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
4.6K
|
2.1M
|
19
|
|
ASX - By Stock
|
RAP |
Re:
BOD Motive?
|
|
delivercn
|
97 |
30K |
22 |
17/04/22 |
17/04/22 |
ASX - By Stock
|
97
|
30K
|
22
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Proposed Acquisition of ResApp Health by Pfizer
|
|
delivercn
|
687 |
254K |
5 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
687
|
254K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Proposed Acquisition of ResApp Health by Pfizer
|
|
delivercn
|
687 |
254K |
0 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
687
|
254K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Proposed Acquisition of ResApp Health by Pfizer
|
|
delivercn
|
687 |
254K |
20 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
687
|
254K
|
20
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Proposed Acquisition of ResApp Health by Pfizer
|
|
delivercn
|
687 |
254K |
8 |
11/04/22 |
11/04/22 |
ASX - By Stock
|
687
|
254K
|
8
|
|
ASX - By Stock
|
GSS |
Re:
Ann: Public Health Wales Awards Enteric Testing Contract to GSS
|
|
delivercn
|
8 |
3.3K |
0 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
8
|
3.3K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
COVID-19 Instant Screening test
|
|
delivercn
|
1.0K |
295K |
1 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
1.0K
|
295K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
COVID-19 Instant Screening test
|
|
delivercn
|
1.0K |
295K |
1 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
1.0K
|
295K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Not selling
|
|
delivercn
|
1 |
1.0K |
1 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
1
|
1.0K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Cough analysis patent granted in China
|
|
delivercn
|
87 |
22K |
10 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
87
|
22K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp receives Advanced and Overseas R&D Finding
|
|
delivercn
|
21 |
7.6K |
4 |
14/09/21 |
14/09/21 |
ASX - By Stock
|
21
|
7.6K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos
|
|
delivercn
|
106 |
30K |
3 |
16/03/21 |
16/03/21 |
ASX - By Stock
|
106
|
30K
|
3
|
|
ASX - By Stock
|
ZGL |
Re:
Ann: Appendix 4D and Half Year Financial Report
|
|
delivercn
|
10 |
3.8K |
1 |
11/03/21 |
11/03/21 |
ASX - By Stock
|
10
|
3.8K
|
1
|
|